Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...
Pasritamig, a first-in-class bispecific T-cell-engaging antibody, shows potential in mCRPC with outpatient dosing designed for the community setting Data show low rates of treatment-related adverse ...
PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. MIAMI, FLORIDA / ACCESS Newswire / November ...
DelveInsight’s Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic ...
A new study has uncovered promising therapeutic strategies against one of the deadliest forms of prostate cancer. McGill University researchers at the Rosalind and Morris Goodman Cancer Institute (GCI ...
Patients with metastatic castration-resistant prostate cancer who received Lu-177-PSMA-617 (Pluvicto) achieved similar overall survival and had fewer serious adverse events compared to those who ...
Researchers at Case Western Reserve University have developed a treatment for advanced prostate cancer that could eliminate a ...
PSA is a validated FDA-recognized clinical endpoint in assessing prostate cancer treatment response; Telomir-1 lowered PSA levels in a dose-related manner. PSA is one of the most widely used and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback